Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $5.17.

Several research analysts have recently weighed in on SGMO shares. Barclays lifted their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, January 27th. Truist Financial lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company cut their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $25,000. JPMorgan Chase & Co. increased its position in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 25,000 shares during the period. SBI Securities Co. Ltd. purchased a new position in Sangamo Therapeutics in the fourth quarter worth $28,000. Finally, Shelton Wealth Management LLC bought a new position in Sangamo Therapeutics in the 4th quarter valued at $29,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Down 1.7 %

Shares of NASDAQ SGMO opened at $1.15 on Wednesday. The company has a market capitalization of $239.95 million, a PE ratio of -1.53 and a beta of 1.30. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $1.40.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.